论文部分内容阅读
目的:探讨乳腺肿瘤患者血清和组织多效蛋白(PTN)表达及其在乳腺肿瘤诊断和预后评估中的价值。方法:选择120例乳腺肿瘤患者(观察组)和100例健康人群(对照组)作为研究对象,采集各组受试对象静脉血3ml,采用酶联免疫吸附试验检测血清PTN含量,同时用化学发光免疫分析法检测血清CA15-3和CEA含量,利用受试者工作曲线(ROC)研究血清PTN对乳腺肿瘤的诊断价值。采用免疫组织化学染色检测观察组肿瘤组织及肿瘤旁组织中PTN表达水平,按照乳腺肿瘤组织PTN表达水平将乳腺肿瘤患者分为PTN高表达组和低表达组,分析PTN表达水平与患者生存预后的关系。结果:观察组血清PTN含量明显高于对照组,2组间比较差异有统计学意义(P<0.05)。在最佳截断值时,PTN诊断乳腺肿瘤的曲线下面积(AUC)为0.947(95%CI:0.916~0.978,P<0.05),血清PTN诊断乳腺肿瘤的AUC高于血清CA15-3、CEA。乳腺肿瘤组织PTN表达评分为7.15±0.49分,肿瘤旁组织PTN表达评分为2.04±0.12分,肿瘤组织PTN表达明显高于肿瘤旁组织(P<0.05);PTN低表达组术后生存时间明显高于PTN高表达组,2组间比较差异有统计学意义(χ2=4.003,P=0.038)。PTN表达与肿瘤直径、淋巴结转移、雌激素受体(ER)表达、孕激素受体(PR)表达、表皮生长因子受体-2(HER2)表达无相关性(P>0.05),PTN高表达组TNM分期更高,分化程度更低(P<0.05)。结论:血清PTN可以作为乳腺肿瘤的辅助诊断,组织PTN表达能够为乳腺肿瘤预后评估提供帮助。
Objective: To investigate the expression of serum and tissue polymorphic protein (PTN) in breast cancer patients and its value in the diagnosis and prognosis evaluation of breast tumors. Methods: 120 breast tumor patients (observation group) and 100 healthy people (control group) were selected as the study subjects. 3 ml blood samples were collected from each group. Serum PTN levels were detected by enzyme-linked immunosorbent assay and chemiluminescence. Serum CA15-3 and CEA levels were measured by immunoassay, and the diagnostic value of serum PTN for breast tumors was investigated using a receiver operating curve (ROC). Immunohistochemical staining was used to detect the expression of PTN in the tumor tissues and paraneoplastic tissues of the observation group. According to the expression level of PTN in the breast tumor tissues, breast cancer patients were divided into high expression group and low expression group of PTN, and the expression level of PTN and prognosis of patients were analyzed. relationship. Results: The serum PTN level in the observation group was significantly higher than that in the control group. The difference between the two groups was statistically significant (P<0.05). At the optimal cut-off value, the area under the curve (AUC) for the diagnosis of breast tumors by PTN was 0.947 (95% CI: 0.916 to 0.978, P<0.05). The AUC for diagnosis of breast tumors by serum PTN was higher than that of serum CA15-3 and CEA. The PTN expression score in mammary tumors was 7.15±0.49 points, and the PTN expression score was 2.04±0.12 points in the paraneoplastic tissues. The expression of PTN in the tumor tissues was significantly higher than that in the paraneoplastic tissues (P<0.05). The postoperative survival time was significantly higher in the low PTN expression group. In the high PTN expression group, the difference between the two groups was statistically significant (χ2=4.003, P=0.038). There was no correlation between PTN expression and tumor diameter, lymph node metastasis, estrogen receptor (ER) expression, progesterone receptor (PR) expression and epidermal growth factor receptor-2 (HER2) expression (P>0.05). The stage of TNM was higher and the degree of differentiation was lower (P<0.05). Conclusion: Serum PTN can be used as an auxiliary diagnosis of breast tumors. The expression of tissue PTN can help to evaluate the prognosis of breast tumors.